Neutrophil-to-lymphocyte ratio was found associated with worse disease recurrence and progression in patients with T1 non–muscle-invasive bladder cancer in some single-center studies. We validated high pretreatment neutrophil-to-lymphocyte ratio (cutoff, 3) as an independent predictor of disease recurrence, progression, and cancer-specific survival in patients with primary T1 HG/G3 non–muscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guérin therapy. Introduction: The aim of this multicenter study was to investigate the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and to validate the NLR cutoff of 3 in a large multi-institutional cohort of patients with primary T1 HG/G3 non–muscle-invasive bladder cancer (NMIBC). Patients and Methods: The study period was from January 2002 through December 2012. A total of 1046 patients with primary T1 HG/G3 who had NMIBC on re-transurethral bladder resection (TURB) who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance from 13 academic institutions were included. Endpoints were time to disease, and recurrence-free (RFS), progression-free (PFS), overall (OS), and cancer-specific survival (CSS). Results: A total of 512 (48.9%) of patients had NLR ≥ 3 prior to TURB. High pretreatment NLR was associated with female gender and residual T1HG/G3 on re-TURB. The 5-year RFS estimates were 9.4% (95% confidence interval [CI], 6.8%-12.4%) in patients with NLR ≥ 3 compared with 58.8% (95% CI, 54%-63.2%) in patients with NLR < 3; the 5-year PFS estimates were 57.1% (95% CI, 51.5%-62.2%) versus 79.2% (95% CI, 74.7%-83%; P <.0001); the 10-year OS estimates were 63.6% (95% CI, 55%-71%) versus 66.5% (95% CI, 56.8%-74.5%; P =.03); the 10-year CSS estimates were 77.4% (95% CI, 68.4%-84.2%) versus 84.3% (95% CI, 76.6%-89.7%; P =.004). NLR was independently associated with disease recurrence (hazard ratio [HR], 3.34; 95% CI, 2.82-3.95; P <.001), progression (HR, 2.18; 95% CI, 1.71-2.78; P <.001) and CSS (HR, 1.65; 95% CI, 1.02-2.66; P =.03). The addition of NLR to a multivariable model that included established features increased its discrimination for predicting of RFS (+6.9%), PFS (+1.8%), and CSS (+1.7%). Conclusions: Pretreatment NLR ≥ 3 was a strong predictor for RFS, PFS, and CSS in patients with primary T1 HG/G3 NMIBC. It could help in the decision-making regarding intensity of therapy and follow-up.
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer / M.D. Vartolomei, M. Ferro, F. Cantiello, G. Lucarelli, S. Di Stasi, R. Hurle, G. Guazzoni, G.M. Busetto, E. De Berardinis, R. Damiano, S. Perdona, P. Verze, R. La Rocca, M. Borghesi, R. Schiavina, E. Brunocilla, G.L. Almeida, P. Bove, E. Lima, G. Grimaldi, R. Autorino, N. Crisan, A.R. Abu Farhan, M. Battaglia, V. Serretta, G.I. Russo, G. Morgia, D. Terracciano, G. Musi, O. de Cobelli, V. Mirone, S.F. Shariat. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 16:6(2018 Dec), pp. 445-452.
|Titolo:||Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer|
|Parole Chiave:||High risk; High-grade; NLR; Progression; Recurrence; Oncology; Urology|
|Settore Scientifico Disciplinare:||Settore MED/24 - Urologia|
|Data di pubblicazione:||dic-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.clgc.2018.07.003|
|Appare nelle tipologie:||01 - Articolo su periodico|